Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
NCT01202786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2012-08-15
Summary
The aim of the study is in cancer of unknown primary (CUP) patients, to compare the cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary tumor site.
Conditions
- Neoplasms, Unknown Primary
Sponsors & Collaborators
-
Clalit Health Services
collaborator OTHER -
Rosetta Genomics
collaborator UNKNOWN -
Teva Branded Pharmaceutical Products R&D, Inc.
lead INDUSTRY
Principal Investigators
-
Salomon Shtemmer, MD · Clalit Health Services
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2011-12-31
- Completion
- 2012-04-30
Countries
- Israel
Study Locations
More Related Trials
-
Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP
NCT01540058 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Cancer Biospecimen Collection Study
NCT04510129 ·Status: RECRUITING
-
Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
NCT05217407 ·Status: RECRUITING
-
Taiwan Cancer Moonshot Project
NCT05248763 ·Status: RECRUITING
-
Microscopy Imaging of Whole-mount Stained Human Tissues
NCT05689112 ·Status: RECRUITING
-
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
NCT02253251 ·Status: RECRUITING
-
Registry Study on Rare Cancers in Korea
NCT06746766 ·Status: RECRUITING
-
Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer
NCT02671045 ·Status: TERMINATED
-
Validation of MMS Test for Cancer Monitoring
NCT02113683 ·Status: TERMINATED
-
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
NCT04025970 ·Status: UNKNOWN
-
Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma
NCT03167476 ·Status: UNKNOWN
-
Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node Metastasis
NCT03868215 ·Status: UNKNOWN
-
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
NCT02092714 ·Status: UNKNOWN
-
Cost of Cancer Diagnosis Using Next-generation Sequencing Targeted Gene Panels in Routine Practice
NCT04656717 ·Status: COMPLETED
-
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
NCT03750994 ·Status: UNKNOWN
-
Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients with Metastatic Malignant Melanoma Treated with Targeted Therapies or Immunotherapy ( MALT )
NCT03493230 ·Status: COMPLETED ·Phase: NA
-
The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells
NCT01879436 ·Status: COMPLETED
-
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991 ·Status: TERMINATED
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
NCT07224750 ·Status: RECRUITING
-
Registry Study in MSI/dMMR Solid Tumors
NCT06004713 ·Status: RECRUITING
-
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
NCT05837884 ·Status: RECRUITING
-
Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids
NCT02546453 ·Status: COMPLETED ·Phase: NA
-
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors
NCT03596593 ·Status: UNKNOWN ·Phase: NA
-
Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer
NCT00876408 ·Status: COMPLETED
-
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
NCT03892096 ·Status: COMPLETED